Insider · CIK 0002028892
Pierre Kyme
Files at ARMP (Armata Pharmaceuticals, Inc.). First filing -, latest -.
Pierre Kyme files SEC Form 4 as officer at ARMP (Armata Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Pierre Kyme has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 14, 2026 | ARMP Armata Pharmaceuticals, Inc. | FTax withholding Common Stock | -1,030 | $10.54 | $11k | 9,461 | Mar 17, 2026 |
| Mar 9, 2026 | ARMP Armata Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +183,142 | $0.00 | $0 | 183,142 | Mar 11, 2026 |
| Mar 14, 2025 | ARMP Armata Pharmaceuticals, Inc. | FTax withholding Common Stock | -1,027 | $1.95 | $2,003 | 10,491 | Apr 25, 2025 |
| Feb 5, 2025 | ARMP Armata Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 7, 2025 |
Questions about Pierre Kyme
Answered from the filings on this page, as of the latest one.
Is Pierre Kyme buying or selling?
Pierre Kyme has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Pierre Kyme's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Pierre Kyme has 0.
Where does Pierre Kyme file Form 4?
Pierre Kyme has filed Form 4 at ARMP (Armata Pharmaceuticals, Inc.) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.